Storia in 2 fonti

Novo Nordisk eyes bolt-on deals as pipeline disappointments pile up

In its second-quarter results, Novo disclosed a partial miss in a Phase 3 diabetes trial of CagriSema. And it ended work on an asset that it got when it bought Inversago Pharma.

Raccontata da

economictimes.indiatimes.com

endpoints.news

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo1 g fa

Novo Nordisk eyes bolt-on deals as pipeline disappointments pile up

In its second-quarter results, Novo disclosed a partial miss in a Phase 3 diabetes trial of CagriSema. And it ended work on an asset that it got when it bought Inversago Pharma.

originale

economictimes.indiatimes.com1 g fa

Novo CEO says setbacks demand faster research, acquisitions as investors fret over pipeline

Novo accelerates acquisitions after pipeline setbacks; Wegovy captures 90% oral obesity market amid patent cliff by 2030s. Obesity market to reach $100B+ annually; Novo's pipeline strength critical against Eli Lilly as semaglutide patent expires.

Leggi questa versione →

Timeline cronologica

mercoledì 5 agosto 2026·economictimes.indiatimes.com
Novo CEO says setbacks demand faster research, acquisitions as investors fret over pipeline
Novo Nordisk CEO Mike Doustdar said the company will speed up research and pursue smaller acquisitions to strengthen its drug pipeline after recent trial setbacks. The company…
mercoledì 5 agosto 2026·endpoints.news
Novo Nordisk eyes bolt-on deals as pipeline disappointments pile up
In its second-quarter results, Novo disclosed a partial miss in a Phase 3 diabetes trial of CagriSema. And it ended work on an asset that it got when it bought Inversago Pharma.